The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma

Cancer, EarlyView.

Source: Cancer - October 23, 2018 Category: Cancer & Oncology Authors: Suman Malempati, Brenda J. Weigel, Yueh ‐Yun Chi, Jing Tian, James R. Anderson, David M. Parham, Lisa A. Teot, David A. Rodeberg, Torunn I. Yock, Barry L. Shulkin, Sheri L. Spunt, William H. Meyer, Douglas S. Hawkins Source Type: research